107 related articles for article (PubMed ID: 12043456)
1. Establishment and characterization of new murine breast cancer cell lines.
Bernhardt G; Beckenlehner K; Spruss T; Schlemmer R; Reile H; Schönenberger H
Arch Pharm (Weinheim); 2002 Mar; 335(2-3):55-68. PubMed ID: 12043456
[TBL] [Abstract][Full Text] [Related]
2. Establishment and Characterization of New Murine Breast Cancer Cell Lines.
Bernhardt G; Beckenlehner K; Spruss T; Schlemmer R; Reile H; Schönenberger H
Arch Pharm (Weinheim); 2002 May; 335(2):55-68. PubMed ID: 12007108
[TBL] [Abstract][Full Text] [Related]
3. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
[TBL] [Abstract][Full Text] [Related]
4. Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.
Bernhardt G; Reile H; Birnböck H; Spruss T; Schönenberger H
J Cancer Res Clin Oncol; 1992; 118(1):35-43. PubMed ID: 1309532
[TBL] [Abstract][Full Text] [Related]
5. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
Spruss T; Bernhardt G; Schickaneder E; Schönenberger H
J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139
[TBL] [Abstract][Full Text] [Related]
6. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
Gust R; Faderl M; Schönenberger H
J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
[TBL] [Abstract][Full Text] [Related]
7. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen.
Darro F; Cahen P; Vianna A; Decaestecker C; Nogaret JM; Leblond B; Chaboteaux C; Ramos C; Pétein M; Budel V; Schoofs A; Pourrias B; Kiss R
Breast Cancer Res Treat; 1998 Sep; 51(1):39-55. PubMed ID: 9877028
[TBL] [Abstract][Full Text] [Related]
9. [Effects of estrogen and endocrine therapeutic agents on the estrogen receptor, progesterone receptor and DNA synthesis in MCF-7 human breast cancer cells using the whole cell uptake method].
Kurebayashi J; Horiuchi R; Nakamura T; Iino Y; Ishida T; Takigawa H; Izuo M
Nihon Naibunpi Gakkai Zasshi; 1987 Nov; 63(11):1351-63. PubMed ID: 2965035
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation.
Whelan RD; Hill BT
Breast Cancer Res Treat; 1993; 26(1):23-39. PubMed ID: 8400321
[TBL] [Abstract][Full Text] [Related]
11. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
Milovanovic SR; Monje E; Szepeshazi K; Radulovic S; Schally A
J Cancer Res Clin Oncol; 1993; 119(5):273-8. PubMed ID: 8382705
[TBL] [Abstract][Full Text] [Related]
12. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo.
Beckenlehner K; Bannke S; Spruss T; Bernhardt G; Schönenberg H; Schiess W
J Cancer Res Clin Oncol; 1992; 118(8):591-6. PubMed ID: 1517281
[TBL] [Abstract][Full Text] [Related]
14. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
Gust R; Karl J; Faderl M; Schönenberger H
Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
[TBL] [Abstract][Full Text] [Related]
15. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
ter Haar E; Day BW
Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
[TBL] [Abstract][Full Text] [Related]
16. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
[TBL] [Abstract][Full Text] [Related]
17. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
Milovanovic SR; Radulovic S; Schally AV
Breast Cancer Res Treat; 1992; 24(2):147-58. PubMed ID: 8443402
[TBL] [Abstract][Full Text] [Related]
19. Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer.
Tantivejkul K; Vucenik I; Eiseman J; Shamsuddin AM
Breast Cancer Res Treat; 2003 Jun; 79(3):301-12. PubMed ID: 12846414
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
